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Understanding the molecular mechanisms inducing and regulating epithelial-to-mesenchymal transition (EMT) upon chronic
intestinal inﬂammation is critical for understanding the exact pathomechanism of inﬂammatory bowel disease (IBD). The aim
of this study was to determine the expression proﬁle of TAM family receptors in an inﬂamed colon. For this, we used a rat
model of experimental colitis and also collected samples from colons of IBD patients. Samples were taken from both inﬂamed
and uninﬂamed regions of the same colon; the total RNA was isolated, and the mRNA and microRNA expressions were
monitored. We have determined that AXL is highly induced in active-inﬂamed colon, which is accompanied with reduced
expression of AXL-regulating microRNAs. In addition, the expression of genes responsible for inducing or maintaining
mesenchymal phenotype, such as SNAI1, ZEB2, VIM, MMP9, and HIF1α, were all signiﬁcantly induced in the active-inﬂamed
colon of IBD patients while the epithelial marker E-cadherin (CDH1) was downregulated. We also show that, in vitro,
monocytic and colonic epithelial cells increase the expression of AXL in response to LPS or TNFα stimuli, respectively. In
summary, we identiﬁed several interacting genes and microRNAs with mutually exclusive expression pattern in active-inﬂamed
colon of IBD patients. Our results shed light onto a possible AXL- and microRNA-mediated regulation inﬂuencing epithelial-to-
mesenchymal transition in IBD.
1. Introduction
Inﬂammatory bowel disease (IBD) is a group of multifacto-
rial disorders characterized by chronic inﬂammation along
the digestive tract, and in combination with lifestyle, it is
associated with genetic and environmental factors [1, 2].
IBD comprises two main types of intestinal inﬂammation:
Crohn’s disease (CD) and ulcerative colitis (UC). While CD
may occur from the mouth to the anus, UC is limited to
the colon [3]. Of note, an increasing incidence of IBD
has been reported worldwide, especially in economically
well-developed countries [4]. As a life-long disease, the main
symptoms of IBD—such as abdominal pain, diarrhea, and
fatigue—are highly reducing the quality of life; in addition,
prolonged inﬂammation increases the risk of colitis-
associated colorectal cancer (CRC) [5]. Inﬂammatory condi-
tions, among others, play roles at diﬀerent steps of tumor
development such as initiation, invasion, metastasis, and
epithelial-to-mesenchymal transition (EMT) [6]. The aber-
rantly functioning common signaling pathways and mole-
cules are able to link immune response and cancer
progression to each other [7]. In line with this, defects in
immune tolerance in the gut against commensal microor-
ganisms or insuﬃcient negative immune regulation may
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cause robust inﬂammation leading to colitis-associated
colorectal cancer [8].
TAM receptors are known, among others, as pleiotropic
negative regulators of the immune system [9, 10]. This family
of cell surface transmembrane receptors has three members:
TYRO3, AXL, and MERTK. Their transmembrane domain
is connected to the extracellular domain comprising tandem
repeats and to the cytoplasmic protein tyrosine kinase
domain, which is responsible for signal transduction after
ligand-activated receptor dimerization [11]. The two ligands
that bind to and activate TAM receptors are growth arrest-
speciﬁc gene 6 (GAS6) and protein S (PROS) which have
distinct expression patterns in mammalian tissues [12].
Apart of inhibiting inﬂammation TAM receptor signaling
has been shown to have important regulatory roles in vascu-
lar smooth-muscle homeostasis, erythropoiesis, and cancer
development [12]. In addition, TAM receptors are promot-
ing inﬂammatory responses; as phagocytic receptors, they
also have a role in the clearance of apoptotic cells and in
stimulating the maturation of natural killer cells [9, 13].
Importantly, AXL impinges on cell motility and invasion
compared to TYRO3 and MERTK [14, 15], while TYRO3
acts as an inhibitor of type 2 immunity during allergic reac-
tions [16]. TAM receptors AXL and MERTK are also known
as protooncogenes: they are highly expressed in numerous
tumor cells [17]. Hence, the therapeutic targeting of AXL
and MERTK kinases is considered an anticancer strategy:
small-molecule inhibitors as well as biologics are in preclini-
cal development [18].
The increased expression of AXL has been reported in
several cancer types, such as lung, breast, and colorectal as
well as head and neck cancer [11]. Furthermore, the AXL
expression level inversely correlates with survival; hence, it
is considered as a strong predictor of poor clinical outcome
[19]. AXL has been shown to act through several signaling
pathways: activation of NF-κB and JAK/STAT leads to the
regulation of immune response and suppression of inﬂam-
mation [12]; in contrast, the activation of transcriptional
factors SNAI1/2, ZEB2, or TWIST stimulates EMT [20, 21];
moreover, AXL mediates tumor invasion by the regulation
of matrix metalloproteinase-9 (MMP9) expression [22].
During EMT, transcription factors induce the breakage of
cell–cell connections through the suppression of epithelial
marker E-cadherin (CDH1), while expression of mesenchy-
malmarkers vimentin (VIM) andMMP9 induces reorganiza-
tion of the extracellular matrix giving rise to mesenchymal
phenotype [23]. Inﬂamed tissues and tumor microenviron-
ment are characterized by limited supplies of oxygen, which
provokes the expression of hypoxia-inducible factor 1 alpha
(HIF1α) [24]. As a consequence, HIF1α induces a NOTCH
signaling pathway, critical in the regulation of EMT-related
transcriptional factors, and also enhances the expression of
AXL [14, 25].
Dysregulated expression of miRNAs has been described
in various cancer types where miRNAs can act as tumor
suppressors or oncogenes [26]. Several miRNAs, such as
miR-34a, miR-199a, and miR-92b, are known to posttran-
scriptionally regulate the expression of AXL [14, 27–29].
For example, miR-34a regulates AXL expression in lung
as well as in head and neck cancer cells, where high
tumor AXL mRNA expression associates with poor survival
[27, 30]; miR-34a and miR-199a reduce the expression of
AXL in non-small-cell lung cancer and colorectal cancer
cell lines [28]; and miR-92b reduces the amount of AXL
in ﬁbroblasts [29, 31].
Deﬁning molecular relationships between chronic
inﬂammation and EMT is critical for understanding the
progression of IBD and colitis-associated CRC. We have
previously shown that, among others, EMT is activated due
to the opposed expression proﬁle of genes and their regulat-
ing microRNAs at the site of inﬂammation in a rat model of
experimental colitis [32]. Here, we show that TAM family
receptor Axl is highly induced in experimental colitis, which
is accompanied with reduced expression of Axl-regulating
microRNAs. In addition, we have now tested the expression
of the selected genes and microRNAs on samples derived
from colons of IBD patients and have determined that the
expression pattern of all tested molecules is the same as in
the case of a rat model of experimental colitis.
2. Materials and Methods
2.1. In Vivo Rat Model and Sample Collection. Experimental
colitis in rats was induced by 2,4,6-trinitrobenzene sulphonic
acid (TNBS) as described previously [32]. Brieﬂy, male
Wistar rats were randomly divided into two groups: the ﬁrst
group served as control (vehicle-treated hence noncolitis-
induced) and the second group was induced by TNBS
(colitis-induced) based on the method described by Morris
et al. [33]. 72 hours after the treatment, all animals were
sacriﬁced, and distal colons were removed. In the case of
the control group, samples were taken from random colon
sections; samples from colitis-induced animals were taken
from inﬂamed colon region as well as from nonadjacent
uninﬂamed region. All samples were kept in a TRIzol reagent
(Thermo Fisher) at −80°C.
2.2. Patients. Colonic biopsies were obtained from 10
consenting patients with IBD (6 females and 4 males; median
age 39 years, 28–48 years) undergoing colonoscopy for diag-
nostic purposes approved by the Hungarian Medical
Research Council’s Committee of Scientiﬁc and Research
Ethics (ETT TUKEB). Sample collection and classiﬁcation
were performed according to the disease status of patients,
active/relapsing or inactive/remission phase. Furthermore,
samples from relapsing patients were subdivided as unin-
ﬂamed or inﬂamed according to the status of the colon tissue.
2.3. Cell Culture Conditions and Stimulations. The human
THP-1 monocytic cells and HT-29 colonic epithelial cells
were maintained in a RPMI-1640 (Gibco) or DMEM (Gibco)
medium, respectively, supplemented with 10% fetal bovine
serum (FBS; Gibco) and 1% antibiotic/antimycotic solution
containing 10,000 units/ml of penicillin, 10,000μg/ml of
streptomycin, and 25μg/ml of amphotericin B (Gibco). Cells
were cultured at 37°C in an atmosphere of 5% v/v CO2 in
air. In order to activate THP-1 cells, the culture medium was
additionally supplemented with 5ng/ml phorbol myristate
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acetate (PMA; Sigma) for 48h prior to the experiment. For
TNFα or LPS treatment, cells were seeded on six-well cell
culture plates (Sarstedt) and stimulated with 1μg/ml LPS
(Sigma) or 10 ng/ml TNFα (R&D Systems) for the indicated
time, followed by RNA extraction.
2.4. Extraction of Total RNA, Reverse Transcription, and
Quantitative Real-Time PCR (QRT-PCR). Samples from rat
colons were homogenized in a TRIzol reagent by an
ULTRA-TURRAX T-18 (IKA) instrument as described
previously [32]. 0.1ml of chloroform (Sigma-Aldrich) was
added to a 0.3ml homogenized sample with vigorous vortex-
ing. The samples were centrifuged at 13000 rpm for 10
minutes. The total RNA was then extracted from the upper
aqueous phase. RNeasy Plus Mini Kit (Qiagen) was used to
purify the total RNA from rat colon samples, as well as
human THP-1 and HT-29 cells, according to the manufac-
turer’s protocol. Human colonic biopsies were obtained by
experienced gastroenterologists at the 1st Department of
Internal Medicine, University of Pécs, in accordance with
the guidelines set out by the Medical Research Council of
Hungary. The total RNA from human biopsies was isolated
using NucleoSpin RNA Kit (Macherey-Nagel) according to
the manufacturer’s protocol. The quality and the quantity
of the extracted RNAs were determined by TapeStation
(Agilent) and Qubit Fluorometer (Thermo Fisher).
Reverse transcription and QRT-PCR were performed as
described previously [32]. All measurements were performed
in duplicate with at least two biological replicates. Speciﬁc
exon spanning primer sets and TaqMan Gene Expression
Assays (Thermo Fisher) are listed in Tables 1 and 2, respec-
tively. The ratio of each mRNA relative to the 18S rRNA
was calculated using the 2−ΔΔCT method. The speciﬁc miRNA
assays (Thermo Fisher) are shown in Table 3. The ratio of
each miRNA relative to the endogenous U6 or RNU48
snRNA for rat or human, respectively, was calculated using
the 2−ΔΔCT method.
2.5. Tissue Sections and Immunoﬂuorescent Labelling. Rat
colons were embedded in Technovit 7100, and tissue sections
of 7μm thickness were cut with Reichert Jung 1140 Autocut
microtome for immunoﬂuorescent staining. Tissue sections
were then blocked for 20 minutes in PBS (Gibco) containing
5% fetal bovine serum (FBS; Gibco) and 0.1% TritonX
(Sigma). Next, sections were incubated overnight with mouse
anti-Axl (Santa Cruz) primary antibody (1 : 100 dilution) or
isotype-matched negative control antibody, washed three
times with PBT (PBS containing TritonX) for 10min each,
incubated with FITC conjugated anti-mouse IgG (Sigma)
secondary antibody (1 : 250 dilution) for 90 minutes, and
washed three times with PBT (10minutes each). Finally,
samples were washed with PBS containing 4′,6-diamidino-
2-phenylindole (DAPI; 1 : 10000 dilution) and mounted in
Citiﬂuor mounting media (Citiﬂuor Ltd.). Samples were
analyzed using epiﬂuorescent illumination of the Axiovision
Z1 ﬂuorescent microscope (Zeiss), and images recorded by
Axiovision software.
2.6. Statistical Analysis and Data Representation. Statistical
evaluations were performed using the IBM SPSS Statistics
program for Windows. Graphs were plotted with GraphPad
Table 1: SYBR Green primer sets used in QPCR experiments.
Gene Forward (5′–3′) Reverse (5′–3′)
CDH1 AGCCTGTCGAAGCAGGATTG AGTCCTGGTCCTCTTCTCCG
MMP9 TCTATGGTCCTCGCCCTGAA GCACAGTAGTGGCCGTAGAA
VIM GGACCAGCTAACCAACGACA AAGGTCAAGACGTGCCAGAG
HIF1α GCCGCTGGAGACACAATCAT CGTTTCAGCGGTGGGTAATG
ZEB2 CCAAGGAGCAGGTAATCGCA ACGTTTCTTGCAGTTTGGGC
SNAI1 ACCCCAATCGGAAGCCTAAC GGACAGAGTCCCAGATGAGC
Snai1 CGGAAGCCCAACTATAGCGA AGAGTCCCAGATGAGGGTGG
Table 2: TaqMan Gene Expression Assays.
Gene Assay number
Axl Rn01457771_m1
Tyro3 Rn00567281_m1
Mertk Rn00576094_m1
Pros1 Rn01527321_m1
Gas6 Rn00588984_m1
AXL Hs00242357_m1
MERTK Hs01031979_m1
TYRO3 Hs00170723_m1
PROS1 Hs00165590_m1
GAS6 Hs00181323_m1
18S RNA Hs99999901_s1
TNFα Hs00174128_m1
SOCS3 Hs01000485_g1
Table 3: miRNA-speciﬁc TaqMan microRNA assays.
miRNA Assay number
RNU48 tm001006
U6 tm001973
miR-199a tm002304
miR-192 tm000491
miR-34a tm000426
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Prism 6 software. Quantitative data are presented as the
mean± SEM, and the signiﬁcance of diﬀerence between sets
of data was determined by one-way analysis of variance
(ANOVA) following LSD post hoc test; a p value of less than
0.05 was considered signiﬁcant.
3. Results and Discussion
3.1. Expression Pattern of TAM Receptors and Their Ligands
in Rat Experimental Colitis. Increasing evidence suggests
the malfunction in the negative regulation of immune
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Figure 1: Diverse expression patterns of TAM receptors and their ligands at the site of colon inﬂammation in rat experimental colitis. The
relative gene expression of TAM receptors Tyro3 (a), Axl (b), and Mertk (c) and their ligands Gas6 (d) and Pros1 (e) as well as the EMT-
inducer Snai1 (f) is shown from control (left columns, n = 2), uninﬂamed (middle columns, n = 6), and inﬂamed (right columns, n = 6) rat
colon sections. (g–i) Protein expression of Axl on rat colon sections. Data on (a–f) are presented as the mean± SEM; ∗p < 0 05. Scale bar
for (g–i): 100μm; blue: DAPI; green: Axl protein.
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Figure 2: Continued.
5Mediators of Inﬂammation
response, thereby robust and prolonged inﬂammation leads
to colitis-associated CRC [11, 12]. Since TAM receptors are
involved in both negative regulation of the immune response
and in tumorigenesis, we ﬁrst sought to analyze their expres-
sion level in rat experimental colitis. We have determined
that the gene expression of Axl is signiﬁcantly induced in
inﬂamed regions of the colon as compared to both controls
and uninﬂamed regions (Figure 1(b)). In contrast, we could
not detect any signiﬁcant change in gene expression of
neither receptors Tyro3 and Mertk (Figures 1(a) and 1(c))
nor ligands Gas6 and Pros1 (Figures 1(d) and 1(e)) as com-
pared to controls. Next, we performed immunoﬂuorescent
labelling using anti-Axl mAb on tissue sections. In line with
the increased gene expression of Axl, we detected a marked
increase of Axl protein in the lamina propria of inﬂamed
regions (Figures 1(g)–1(i)). Given that AXL exerts a wide
array of functions including immune regulation, clearance
of dead cells, cell survival, proliferation, migration, and adhe-
sion [34], it is diﬃcult to conclude which process is aﬀected
by its increased expression in experimental colitis.
3.2. Association of Axl with EMT in Rat Experimental Colitis.
AXL is associated with mesenchymal phenotype [35] with
increased expression in non-small-cell lung cancer cell lines
[36]. The knockdown of AXL in MDA-MB-231 breast cancer
cell line reduced the expression of mesenchymal marker
vimentin [37]. In contrast, AXL overexpression led to the
elevated expression of EMT inducers, such as SNAI1, and
repression of CDH1 in breast cancer stem cells [21]. We have
previously reported the induction of EMT-related genes
including Vim and Zeb2 in the inﬂamed rat colon samples
accompanied with decreased expression of epithelial marker
E-cadherin (Cdh1) [32]. Here, we show that in parallel with
increased Axl expression (Figure 1(b)), Snai1 is also
upregulated in inﬂamed regions of rat colons (Figure 1(f)).
These data suggest that the increased expression of Axl in
rat experimental colitis may trigger the expression of EMT
inducers Zeb2 and Snai1, thereby linking increased Axl
expression to EMT.
3.3. AXL and EMT Genes Show Altered Expression Pattern in
IBD Patients. In relapsing disorders, such as IBD, active and
inactive/remission intervals alternate. In the active phase,
symptoms manifest and inﬂammation ﬂames up with dam-
aged and phenotypically intact regions sporadically following
each other along the gut lumen [38]. We have shown that in
the case of rat experimental colitis, several genes and miR-
NAs show distinct expression patterns between uninﬂamed
and inﬂamed regions of colitis-induced colons [32]. Thus,
we have collected colonic biopsies from IBD patients simi-
larly to our sampling model applied in the case of rat exper-
imental colitis. Two samples from the colons of IBD patients
in active phase were collected: one sample corresponds to the
phenotypically uninﬂamed region while the other to the
severely inﬂamed region, referred to as active-uninﬂamed
and active-inﬂamed, respectively.
Next, we determined the expression of TAM receptors
and their ligands GAS6 and PROS1 as well as genes involved
in EMT on these samples. In the case of TAM receptors and
their ligands, only AXL was signiﬁcantly induced in the
active-inﬂamed colon biopsies compared to both the inactive
and the active-uninﬂamed samples (Figures 2(a)–2(e)).
Recent reports have shown that AXL regulates EMT through
the activation of SNAI1, ZEB2, and MMP9 in several human
malignancies [20, 21]. In line with these data, all three genes
were signiﬁcantly induced in the active-inﬂamed regions of
relapsing IBD patients (Figures 2(f)–2(h)). These data are
in agreement with those observed in rat experimental colitis
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Figure 2: Distinct expression of genes and microRNA regulating epithelial-to-mesenchymal transition in IBD patients. The relative gene
expression of TAM receptors TYRO3 (a), AXL (b), and MERTK (c); their receptors GAS6 (d) and PROS1 (e); and genes involved in
epithelial-to-mesenchymal transition SNAI1 (f), ZEB2 (g), MMP9 (h), CDH1 (i), VIM (j), and HIF1α (k) as well as microRNA miR-192 (l)
are shown from inactive (left, n = 5), active-uninﬂamed (middle, n = 7), and active-inﬂamed (right, n = 5) colon samples of IBD patients.
Dots and lines represent individual values and the mean, respectively; ∗p < 0 05.
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(Figure 1(f) [32]). The main role of the increased ZEB2 in
EMT is the suppression of E-cadherin coding CDH1 gene
[39]. In line with this and our earlier data [32], the expression
of CDH1 was signiﬁcantly downregulated in active-inﬂamed
regions (Figure 2(i)). Elevated MMP9 and vimentin are
responsible for the formation of mesenchymal phenotype
and the maintenance of microenvironment by, among
others, inducing HIF1α [23, 24]. We have determined that
all these genes were upregulated in the active-inﬂamed
regions of relapsing IBD patients (Figures 2(h), 2(j), and
2(k)) corroborating earlier data from rat experimental colitis
[32]. Taken together, these data suggest that EMT takes place
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Figure 3: Decreased expression of miRNAs regulating Axl in inﬂamed colon. The relative expression of miR-199a (a, b) and miR-34a (c, d) is
shown from rat (a, c) and human (b, d) samples. Data on panels (a) and (c) represent control (left columns, n = 2), uninﬂamed (middle
columns, n = 6), and inﬂamed (right columns, n = 6) rat colon sections and are presented as the mean± SEM; data on panels (b) and (d)
represent inactive (left, n = 5), active-uninﬂamed (middle, n = 7), and active-inﬂamed (right, n = 5) colon samples of IBD patients where
dots and lines represent individual values and the mean; ∗p < 0 05.
7Mediators of Inﬂammation
in the active-inﬂamed regions of IBD patients in which AXL
may play a regulatory role.
3.4. Dysregulated MicroRNA Expression Drives EMT in IBD.
Altered expression of miRNAs is a hallmark of various can-
cer types. MicroRNAs regulating genes involved in EMT,
such as miR-192 and miR-375, are downregulated in the
inﬂamed colon regions in rat experimental colitis [32] and
also in active-inﬂamed colons of IBD patients (Figure 2(l)).
Importantly, microRNAs miR-199a and miR-34a, which
posttranscriptionally regulate the expression of AXL [27–29],
are also signiﬁcantly downregulated in inﬂamed rat colons
(Figures 3(a) and 3(c)) as well as in active-inﬂamed regions
of IBD patients (Figures 3(b) and 3(d)). As a consequence,
the posttranscriptional regulation of AXL is dysregulated;
hence, its transcript (Figures 1(b) and 2(b)) and protein
(Figure 1(i)) levels increase.
3.5. LPS Induces AXL Expression in THP-1 Monocytic Cell
Line. TAM receptors exhibit diﬀerent tissue expression
patterns, and their promoters are regulated by distinct extra-
cellular stimuli [40, 41]. Next, we have used inactivated and
PMA-activated THP-1 cell line of monocytic origin to deter-
mine if the LPS challenge alters the expression of TAM
receptors. For this, we have stimulated the cells for 3 or 24
hours with LPS and have ﬁrst determined the expression of
TNFα as a positive control of induction. As expected, both
inactivated and activated THP-1 cells responded with ele-
vated expression of TNFα (Figures 4(a) and 4(b)). The
expression of TAM receptors showed diverse expressions:
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Figure 4: Distinct expression of TAM receptors in LPS triggered THP-1 and TNFα triggered HT-29 cells. The relative gene expression of the
proinﬂammatory molecule TNFα, TAM receptors TYRO3, AXL, and MERTK, and the suppressor of cytokine signalling SOCS-3 in (a)
inactivated LPS-stimulated THP-1, (b) PMA-activated LPS-stimulated THP-1, and (c) TNFα-stimulated HT-29 cells. Data are presented
as the mean± SEM; n = 3; ∗p < 0 05.
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while LPS downregulated the expression of TYRO3 and
MERTK, it signiﬁcantly induced the expression of AXL
(Figures 4(a) and 4(b)). Interestingly, while the expression
of AXL in inactivated THP-1 cells shows modest induction
at both 3 and 24 hours post LPS stimuli (Figure 4(a)), induc-
tion in activated THP-1 cells at 24 hours after LPS challenge
is robust (Figure 4(b)). Since TAM receptors inhibit TLR-
induced inﬂammation by the activation of, among others,
SOCS3 anti-inﬂammatory molecule [13], we have next deter-
mined its expression. The expression pattern of SOCS3
(Figures 4(a) and 4(b)) follows that of TNFα that is opposing
expression pattern to that of AXL suggesting that even
though increased AXL may act as a negative regulator of
innate immunity upon LPS stimulation of THP-1 cells, the
downstream eﬀector molecule is probably not SOCS3.
3.6. TNFα Induces Gene Expression of AXL in HT-29 Colonic
Epithelial Cell Line. In order to determine if TAM receptors
show altered expression in colonic epithelial cells, we have
stimulated HT-29 colonic epithelial cells with TNFα for 6
or 24 hours and have again ﬁrst monitored the expression
of TNFα which is known to be self-induced. The robust
expression of TNFα indicated successful induction of
HT-29 cells (Figure 4(c)). AXL again showed induced expres-
sion at 24 hours postinduction (Figure 4(c)). Importantly, in
contrast to THP-1 cells, the expression of SOCS3 remained
unaltered (Figure 4(c)) suggesting that the function of
induced AXL in these cells is probably not the inhibition of
inﬂammation, at least not through SOCS3. Finally, the
expression of both miR-192 and miR-34a showed signiﬁcant
downregulation at 24 hours post-TNFα stimuli (Figures 5(a)
and 5(b), resp.). These data are in complete agreement with
those obtained from both rat and human colon samples indi-
cating that TNFα-stimulated HT-29 cells are mimicking
in vivo observations making them a perfect in vitro system
for modelling the gene expression changes of colonic epithe-
lial cells in IBD.
4. Conclusion
Our present study demonstrates that the epithelial-to-
mesenchymal transition is triggered in IBD patients. These
data are in agreement with our previous report showing the
activation of EMT in rat experimental colitis [33]. In
addition, we show that the increased expression of AXL is
accompanied with the decreased expression of its microRNA
regulators. These ﬁndings shed light onto a possible AXL-
and microRNA-mediated regulation inﬂuencing epithelial-
to-mesenchymal transition in IBD. In addition, by using
in vitro monocytic and colonic epithelial cells, we show that
upon stimulation with LPS or TNFα, respectively, the expres-
sion of AXL increases in both cell types.
Rothlin et al. in a recent review have underlined an
apparently contradicting role of TAM receptors in the con-
text of IBD and CRC, asking if individual members of the
TAM family have tumor-promoting or antitumor eﬀects
[16]. The present study provides preliminary evidence on
the possible oncogenic role of AXL in IBD: the increased
expression of AXL—possibly due to the downregulated
expression of its microRNA regulator/s, such as miR-199a
and miR-34a—along with malfunctioning of the negative
regulation of inﬂammation points toward AXL indeed being
an important player in bridging IBD and CRC. Since the
therapeutic targeting of AXL inhibits tumor growth and
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Figure 5: Decreased expression of miRNAs regulating Axl in TNFα triggered HT-29 colonic epithelial cells. The relative gene expression of
miR-199a (a) and miR-34a (b) is shown from TNFα triggered HT-29 cells. Data are presented as the mean± SEM; n = 3; ∗p < 0 05.
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metastasis in ovarian cancer models [42], it is likely that
AXL may become a potential therapeutic target in colitis-
associated colorectal cancer.
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